$LUMO
Lumos Pharma Inc Stock $lumo

$lumo Overview Financials Valuation SEC Filings Company Website

2016 Q1 Form 10-Q Financial Statement

#000112623416000259 Filed on April 29, 2016

Income Statement

Concept	2016 Q1	2015 Q4	2015 Q1
Revenue	$5.708M	$7.652M	$39.20M
YoY Change	-85.44%	-95.48%	11635.03%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.200M	$7.700M	$8.400M
YoY Change	9.52%	-7.23%	154.55%
% of Gross Profit
Research & Development	$21.94M	$14.80M	$17.98M
YoY Change	22.0%	24.37%	181.52%
% of Gross Profit
Depreciation & Amortization	$595.0K	$500.0K	$300.0K
YoY Change	98.33%	66.67%	0.0%
% of Gross Profit
Operating Expenses	$31.10M	$22.50M	$26.35M
YoY Change	18.04%	11.39%	173.37%
Operating Profit	-$25.39M	-$14.83M	$12.85M
YoY Change	-297.64%	-109.95%	-238.09%
Interest Expense	$7.000K	$0.00	$0.00
YoY Change
% of Operating Profit			0.0%
Other Income/Expense, Net	$39.00K	$0.00	$11.00K
YoY Change	254.55%		-83.82%
Pretax Income	-$25.35M	-$14.80M	$12.86M
YoY Change	-297.17%	-109.93%	-239.23%
Income Tax	-$1.634M	$6.700M	$1.669M
% Of Pretax Income			12.98%
Net Earnings	-$23.72M	-$21.57M	$11.19M
YoY Change	-311.97%	-117.98%	-221.16%
Net Earnings / Revenue	-415.56%	-281.94%	28.55%
Basic Earnings Per Share	-$0.82	-$0.75	$0.40
Diluted Earnings Per Share	-$0.82	-$0.75	$0.35
COMMON SHARES
Basic Shares Outstanding	28.86M shares	28.79M shares	28.22M shares
Diluted Shares Outstanding	28.86M shares		31.92M shares

Balance Sheet

Concept	2016 Q1	2015 Q4	2015 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$178.0M	$197.8M	$214.4M
YoY Change	-16.98%	-2.47%	155.24%
Cash & Equivalents	$177.0M	$195.6M	$206.6M
Short-Term Investments	$1.000M	$2.200M	$7.800M
Other Short-Term Assets	$2.800M	$5.000M	$11.20M
YoY Change	-75.0%	-39.76%	1500.0%
Inventory
Prepaid Expenses	$2.832M	$4.954M	$11.22M
Receivables
Other Receivables
Total Short-Term Assets	$189.4M	$208.1M	$251.1M
YoY Change	-24.56%	-6.92%	194.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$10.50M	$10.40M	$8.028M
YoY Change	30.77%	36.86%	24.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$10.50M	$10.40M	$8.028M
YoY Change	30.77%	36.86%	24.77%
TOTAL ASSETS
Total Short-Term Assets	$189.4M	$208.1M	$251.1M
Total Long-Term Assets	$10.50M	$10.40M	$8.028M
Total Assets	$199.9M	$218.5M	$259.1M
YoY Change	-22.85%	-5.48%	182.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.039M	$3.661M	$4.113M
YoY Change	-26.11%	51.78%	323.15%
Accrued Expenses	$11.07M	$8.761M	$9.295M
YoY Change	19.04%	-6.47%	290.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$164.0K	$558.0K	$555.0K
YoY Change	-70.45%	255.41%	192.11%
Total Short-Term Liabilities	$15.31M	$14.84M	$17.56M
YoY Change	-12.85%	-40.69%	383.54%
LONG-TERM LIABILITIES
Long-Term Debt	$453.0K	$368.0K	$494.0K
YoY Change	-8.3%	-60.89%	-49.9%
Other Long-Term Liabilities	$7.400M	$7.600M	$8.200M
YoY Change	-9.76%	-8.43%	12.33%
Total Long-Term Liabilities	$7.805M	$7.928M	$8.734M
YoY Change	-10.64%	-14.42%	5.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$15.31M	$14.84M	$17.56M
Total Long-Term Liabilities	$7.805M	$7.928M	$8.734M
Total Liabilities	$23.11M	$22.77M	$26.30M
YoY Change	-12.12%	-33.59%	120.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$104.1M	-$80.35M	-$21.93M
YoY Change	374.59%	101.08%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$771.0K	$771.0K	$491.0K
YoY Change	57.03%	247.3%	169.78%
Treasury Stock Shares	24.03K shares	24.03K shares
Shareholders Equity	$176.8M	$195.8M	$232.8M
YoY Change
Total Liabilities & Shareholders Equity	$199.9M	$218.5M	$259.1M
YoY Change	-22.85%	-5.48%	182.45%

Cashflow Statement

Concept	2016 Q1	2015 Q4	2015 Q1
OPERATING ACTIVITIES
Net Income	-$23.72M	-$21.57M	$11.19M
YoY Change	-311.97%	-117.98%	-221.16%
Depreciation, Depletion And Amortization	$595.0K	$500.0K	$300.0K
YoY Change	98.33%	66.67%	0.0%
Cash From Operating Activities	-$19.50M	-$8.400M	-$2.300M
YoY Change	747.83%	-106.43%	-62.3%
INVESTING ACTIVITIES
Capital Expenditures	$281.0K	-$500.0K	$733.0K
YoY Change	-61.66%	25.0%	688.17%
Acquisitions
YoY Change
Other Investing Activities	$1.200M	$1.000M	$4.600M
YoY Change	-73.91%	-76.74%
Cash From Investing Activities	$902.0K	$500.0K	$3.885M
YoY Change	-76.78%	-87.18%	-4277.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	-$43.00K		-$14.67M
YoY Change	-99.71%		-48.75%
Debt Paid & Issued, Net	$72.00K		$39.00K
YoY Change	84.62%		2.63%
Cash From Financing Activities	-$29.00K	6.400M	$14.63M
YoY Change	-100.2%	33.33%	-48.83%
NET CHANGE
Cash From Operating Activities	-19.50M	-8.400M	-2.300M
Cash From Investing Activities	$902.0K	500.0K	$3.885M
Cash From Financing Activities	-$29.00K	6.400M	$14.63M
Net Change In Cash	$873.0K	-1.500M	$18.51M
YoY Change	-95.28%	-101.08%	-35.03%
FREE CASH FLOW
Cash From Operating Activities	-$19.50M	-$8.400M	-$2.300M
Capital Expenditures	$281.0K	-$500.0K	$733.0K
Free Cash Flow	-$19.78M	-$7.900M	-$3.033M
YoY Change	552.19%	-106.03%	-51.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q1	dei	Amendment Flag AmendmentFlag	false
CY2016Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2016Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016Q1	dei	Document Period End Date DocumentPeriodEndDate	2016-03-31
CY2016Q1	dei	Document Type DocumentType	10-Q
CY2016Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001126234
CY2016Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28861315	shares
CY2016Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2016Q1	dei	Entity Registrant Name EntityRegistrantName	NEWLINK GENETICS CORP
CY2016Q1	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016Q1	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015Q4	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	195620000	USD
CY2016Q1	nlnk	Cash And Cash Equivalents Excluding Certificates Of Deposit CashAndCashEquivalentsExcludingCertificatesOfDeposit	176986000	USD
CY2015Q4	nlnk	Contractmanufacturingorganizationequipment Contractmanufacturingorganizationequipment	1075000	USD
CY2016Q1	nlnk	Contractmanufacturingorganizationequipment Contractmanufacturingorganizationequipment	1075000	USD
CY2014Q4	nlnk	Genentech Upfront Payments GenentechUpfrontPayments	150000000	USD
CY2015Q1	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	257000	USD
CY2016Q1	nlnk	Increase Decrease In State Research And Development Credit Receivable IncreaseDecreaseInStateResearchAndDevelopmentCreditReceivable	130000	USD
CY2015Q4	nlnk	Lab Equipment LabEquipment	5832000	USD
CY2016Q1	nlnk	Lab Equipment LabEquipment	6095000	USD
CY2015Q1	nlnk	Merck One Time Milestones MerckOneTimeMilestones	20000000	USD
CY2014Q4	nlnk	Merck Upfront Payments MerckUpfrontPayments	30000000	USD
CY2015Q1	nlnk	Revenuefromgovernmentgrants Revenuefromgovernmentgrants	9600000	USD
CY2016Q1	nlnk	Revenuefromgovernmentgrants Revenuefromgovernmentgrants	3900000	USD
CY2015Q4	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2016Q1	nlnk	Royalty Obligation Payable Noncurrent RoyaltyObligationPayableNoncurrent	6000000	USD
CY2015Q4	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	0	USD
CY2016Q1	nlnk	State Research And Development Credit Receivable StateResearchAndDevelopmentCreditReceivable	130000	USD
CY2015Q4	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	16916000	USD
CY2016Q1	nlnk	Total Leasehold Improvements And Equipment TotalLeaseholdImprovementsAndEquipment	17609000	USD
CY2015Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	5388000	USD
CY2016Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	6684000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3661000	USD
CY2016Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3039000	USD
CY2015Q4	us-gaap	Accrued Fees And Other Revenue Receivable AccruedFeesAndOtherRevenueReceivable	4100000	USD
CY2016Q1	us-gaap	Accrued Fees And Other Revenue Receivable AccruedFeesAndOtherRevenueReceivable	4600000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8761000	USD
CY2016Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11065000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6516000	USD
CY2016Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7111000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	276610000	USD
CY2016Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	281368000	USD
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3200000	USD
CY2016Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4700000	USD
CY2015Q4	us-gaap	Assets Assets	218542000	USD
CY2016Q1	us-gaap	Assets Assets	199923000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	208142000	USD
CY2016Q1	us-gaap	Assets Current AssetsCurrent	189425000	USD
CY2015Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	53000	USD
CY2016Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	181000	USD
CY2015Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	13000	USD
CY2016Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	84000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190404000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	206593000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	195620000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	176986000	USD
CY2015Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	16189000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18634000	USD
CY2015Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	2180000	USD
CY2016Q1	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	997000	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2016Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28838176	shares
CY2016Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28884959	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28814142	shares
CY2016Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28860925	shares
CY2015Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	288000	USD
CY2016Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	289000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	96000	USD
CY2016Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	89000	USD
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1153000	USD
CY2016Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1129000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	892000	USD
CY2016Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	864000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	407000	USD
CY2016Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	223000	USD
CY2015Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	304000	USD
CY2016Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	595000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.40
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
CY2015Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.35
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2016Q1	us-gaap	Extinguishment Of Debt Amount ExtinguishmentOfDebtAmount	397000	USD
CY2015Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-4618000	USD
CY2016Q1	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-1183000	USD
CY2015Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2016Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	397000	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8366000	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9164000	USD
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	12859000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1634000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-25354000	USD
CY2015Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1669000	USD
CY2015Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	255000	USD
CY2016Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	1796000	USD
CY2016Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	1021000	USD
CY2015Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	0	USD
CY2015Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1629000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1501000	USD
CY2015Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	1414000	USD
CY2016Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-2655000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	21000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	31000	USD
CY2015Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-9549000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-212000	USD
CY2015Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	7330000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1296000	USD
CY2015Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2892000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-2122000	USD
CY2015Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	3700687	shares
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2015Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	6000	USD
CY2016Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	7000	USD
CY2015Q1	us-gaap	Interest Paid InterestPaid	6000	USD
CY2016Q1	us-gaap	Interest Paid InterestPaid	7000	USD
CY2015Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	17000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	46000	USD
CY2015Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7427000	USD
CY2016Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	7592000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	22768000	USD
CY2016Q1	us-gaap	Liabilities Liabilities	23110000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	218542000	USD
CY2016Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	199923000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14840000	USD
CY2016Q1	us-gaap	Liabilities Current LiabilitiesCurrent	15305000	USD
CY2015Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	939000	USD
CY2016Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	701000	USD
CY2015Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7928000	USD
CY2016Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	7805000	USD
CY2015Q1	us-gaap	Licenses Revenue LicensesRevenue	29546000	USD
CY2016Q1	us-gaap	Licenses Revenue LicensesRevenue	1370000	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	558000	USD
CY2016Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	164000	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	368000	USD
CY2016Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	453000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14625000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-29000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3885000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	902000	USD
CY2015Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2321000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19507000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-23720000	USD
CY2015Q1	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	0	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Other Assets Acquired1 NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1	231000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	11190000	USD
CY2016Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	397000	USD
CY2015Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11000	USD
CY2015Q1	us-gaap	Operating Expenses OperatingExpenses	26347000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	31101000	USD
CY2015Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	12848000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-25393000	USD
CY2015Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	39000	USD
CY2015Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	269000	USD
CY2016Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	USD
CY2015Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	733000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	281000	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2016Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.00	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2016Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2015Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4954000	USD
CY2016Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2832000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14942000	USD
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	43000	USD
CY2015Q1	us-gaap	Profit Loss ProfitLoss	11190000	USD
CY2016Q1	us-gaap	Profit Loss ProfitLoss	-23720000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2582000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2847000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10400000	USD
CY2016Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10498000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	9000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	33000	USD
CY2015Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	39000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	39000	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17981000	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21937000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-80353000	USD
CY2016Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-104073000	USD
CY2015Q1	us-gaap	Revenue From Grants RevenueFromGrants	9649000	USD
CY2016Q1	us-gaap	Revenue From Grants RevenueFromGrants	4338000	USD
CY2015Q1	us-gaap	Revenues Revenues	39195000	USD
CY2016Q1	us-gaap	Revenues Revenues	5708000	USD
CY2015Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3191000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4716000	USD
CY2015Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	105800	shares
CY2016Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	115566	shares
CY2016Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	46783	shares
CY2016Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4716000	USD
CY2016Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	43000	USD
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	195774000	USD
CY2016Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	176813000	USD
CY2015Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	859000	USD
CY2016Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	0	USD
CY2015Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	24034	shares
CY2016Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	24034	shares
CY2015Q4	us-gaap	Treasury Stock Value TreasuryStockValue	771000	USD
CY2016Q1	us-gaap	Treasury Stock Value TreasuryStockValue	771000	USD
CY2015Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	3600000	USD
CY2016Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	1100000	USD
CY2015Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31919318	shares
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28856944	shares
CY2015Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28218631	shares
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28856944	shares
CY2016Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">D</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">escription of Business</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 4, 1999, NewLink Genetics Corporation (NewLink) was incorporated as a Delaware corporation. NewLink was formed for the purpose of developing treatments for patients with cancer and other diseases. NewLink initiated operations in April 2000. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2005, NewLink created a partially owned subsidiary, BioProtection Systems Corporation (BPS). NewLink contributed certain licensing agreements and other intangible assets for BPS to create vaccines against potential biological terror threats. On January 7, 2011, NewLink acquired all of the minority interest in BPS by merging a newly formed subsidiary of NewLink with BPS, with BPS as the surviving corporation, resulting in NewLink owning all the outstanding capital stock of BPS.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2013, NewLink created a wholly-owned subsidiary, NewLink International (NI). NewLink plans to conduct all or a portion of its operations outside of the United States through NI. In 2014, NewLink created another wholly owned subsidiary, NewLink Global (NG), which was subsequently merged into NewLink during 2014.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NewLink and its subsidiaries (the Company) are devoting substantially all of their efforts toward research and development. The Company has never earned revenue from commercial sales of its drugs. The Company incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$23.7 million</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">three months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">March 31, 2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and for the </font><font style="font-family:inherit;font-size:10pt;">three months then ended</font><font style="font-family:inherit;font-size:10pt;"> have been prepared assuming the Company will continue as a going concern. The Company successfully raised net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$37.6 million</font><font style="font-family:inherit;font-size:10pt;"> from its IPO, completed a follow-on offering of its common stock raising net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$49.0 million</font><font style="font-family:inherit;font-size:10pt;">, and raised an additional </font><font style="font-family:inherit;font-size:10pt;">$58.7 million</font><font style="font-family:inherit;font-size:10pt;"> in net proceeds from the at the market (ATM) offering. In connection with two license and collaboration agreements the Company entered into during 2014, the Company received a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Genentech Inc., a member of the Roche Group, or Genentech, in 2014, and a nonrefundable upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$30.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck, Sharpe and Dohme Corp., or Merck, in 2014, as well as a milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> from Merck in February 2015. The Company's cash and cash equivalents after these agreements and offerings are expected to be adequate to satisfy the Company's liquidity requirements into 2017, although not through commercialization and launch of revenue-producing products. If available liquidity becomes insufficient to meet the Company’s operating obligations as they come due, the Company's plans include pursuing alternative funding arrangements and/or reducing expenditures as necessary to meet the Company’s cash requirements. However, there is no assurance that, if required, the Company will be able to raise additional capital or reduce discretionary spending to provide the required liquidity. Failure by the Company to successfully execute its plans or otherwise address its liquidity needs may have a material adverse effect on its business and financial position, and may materially affect the Company’s ability to continue as a going concern.</font></div></div>
CY2016Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001126234-16-000259-index-headers.html	Edgar Link	pending
0001126234-16-000259-index.html	Edgar Link	pending
0001126234-16-000259.txt	Edgar Link	pending
0001126234-16-000259-xbrl.zip	Edgar Link	pending
a108png.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hyperacutepipelinea02.jpg	Edgar Link	pending
idopipelinea02.jpg	Edgar Link	pending
newlinklogorgbwtaga01a01a04.jpg	Edgar Link	pending
nlnk-20160331.xml	Edgar Link	completed
nlnk-20160331.xsd	Edgar Link	pending
nlnk-20160331x10q.htm	Edgar Link	pending
nlnk-20160331xex1010.htm	Edgar Link	pending
nlnk-20160331xex108.htm	Edgar Link	pending
nlnk-20160331xex109.htm	Edgar Link	pending
nlnk-20160331xex311.htm	Edgar Link	pending
nlnk-20160331xex312.htm	Edgar Link	pending
nlnk-20160331xex321.htm	Edgar Link	pending
nlnk-20160331_cal.xml	Edgar Link	unprocessable
nlnk-20160331_def.xml	Edgar Link	unprocessable
nlnk-20160331_lab.xml	Edgar Link	unprocessable
nlnk-20160331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LUMO
Lumos Pharma Inc Stock $lumo

2016 Q1 Form 10-Q Financial Statement

#000112623416000259 Filed on April 29, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO Lumos Pharma Inc Stock $lumo

2016 Q1 Form 10-Q Financial Statement

#000112623416000259 Filed on April 29, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LUMO
Lumos Pharma Inc Stock $lumo